Genetically Engineered Live Attenuated Influenza A Virus Vaccine Candidates

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 1997 Apr 1

PMID 9060631

Citations 9

Authors

N T Parkin

P Chiu

K Coelingh

Affiliations

Soon will be listed here.

Abstract

We have generated new influenza A virus live attenuated vaccine candidates by site-directed mutagenesis and reverse genetics. By mutating specific amino acids in the PB2 polymerase subunit, two temperature-sensitive (ts) attenuated viruses were obtained. Both candidates have 38 degrees C shutoff temperatures in MDCK cells, are attenuated in the respiratory tracts of mice and ferrets, and have very low reactogenicity in ferrets. Infection of mice or ferrets with either mutant conferred significant protection from challenge with the homologous wild-type virus. Three tests for genetic stability were used to assess the propensity for reversion to virulence: 14 days of replication in nude mice, growth at 37 degrees C in tissue culture, and serial passage in ferrets. One candidate, which contains mutations intended to reduce the ability of PB2 to bind to cap structures, was stable in all three assays, whereas the second candidate, which contains mutations found only in other ts strains of influenza virus, lost its ts phenotype in the last two assays. This approach has therefore enabled the creation of live attenuated influenza A virus vaccine candidates suitable for human testing.

Citing Articles

The impact of the suppression of highly connected protein interactions on the corona virus infection.

Torres F, Kiwi M, Schuller I Sci Rep. 2022; 12(1):9188.

PMID: 35654986 PMC: 9160517. DOI: 10.1038/s41598-022-13373-0.

The Preparation of Chicken Kidney Cell Cultures for Virus Propagation.

Lokhman E, Rai S, Matthews W Methods Mol Biol. 2020; 2203:89-95.

PMID: 32833206 DOI: 10.1007/978-1-0716-0900-2_7.

Reversion of Cold-Adapted Live Attenuated Influenza Vaccine into a Pathogenic Virus.

Zhou B, Meliopoulos V, Wang W, Lin X, Stucker K, Halpin R J Virol. 2016; 90(19):8454-63.

PMID: 27440882 PMC: 5021423. DOI: 10.1128/JVI.00163-16.

Traditional and new influenza vaccines.

Wong S, Webby R Clin Microbiol Rev. 2013; 26(3):476-92.

PMID: 23824369 PMC: 3719499. DOI: 10.1128/CMR.00097-12.

Engineering temperature sensitive live attenuated influenza vaccines from emerging viruses.

Zhou B, Li Y, Speer S, Subba A, Lin X, Wentworth D Vaccine. 2012; 30(24):3691-702.

PMID: 22449422 PMC: 3595159. DOI: 10.1016/j.vaccine.2012.03.025.

References

Fedson D . Influenza and pneumococcal vaccination of the elderly: newer vaccines and prospects for clinical benefits at the margin. Prev Med. 1994; 23(5):751-5. DOI: 10.1006/pmed.1994.1129. View

Ishida T, Katsuta M, Inoue M, Yamagata Y, Tomita K . The stacking interactions in 7-methylguanine-tryptophan systems, a model study for the interaction between the 'cap' structure of mRNA and its binding protein. Biochem Biophys Res Commun. 1983; 115(3):849-54. DOI: 10.1016/s0006-291x(83)80012-6. View

Powers D, Fries L, Murphy B, Thumar B, Clements M . In elderly persons live attenuated influenza A virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory. J Clin Microbiol. 1991; 29(3):498-505. PMC: 269808. DOI: 10.1128/jcm.29.3.498-505.1991. View

Subbarao E, Kawaoka Y, Murphy B . Rescue of an influenza A virus wild-type PB2 gene and a mutant derivative bearing a site-specific temperature-sensitive and attenuating mutation. J Virol. 1993; 67(12):7223-8. PMC: 238184. DOI: 10.1128/JVI.67.12.7223-7228.1993. View

Fazekas G, Rosenwirth B, DUKOR P, Gergely J, Rajnavolgyi E . IgG isotype distribution of local and systemic immune responses induced by influenza virus infection. Eur J Immunol. 1994; 24(12):3063-7. DOI: 10.1002/eji.1830241222. View

SNYDER M, Betts R, DeBorde D, Tierney E, Clements M, Herrington D . Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines. J Virol. 1988; 62(2):488-95. PMC: 250559. DOI: 10.1128/JVI.62.2.488-495.1988. View

Glezen W . Serious morbidity and mortality associated with influenza epidemics. Epidemiol Rev. 1982; 4:25-44. DOI: 10.1093/oxfordjournals.epirev.a036250. View

Massicot J, Murphy B, Thierry F, Markoff L, Huang K, Chanock R . Temperature-sensitive mutants of influenza virus. Identification of the loci of the two ts lesions in the Udorn-ts-1A2 donor virus and the correlation of the presence of these two ts lesions with a predictable level of attenuation. Virology. 1980; 101(1):242-9. DOI: 10.1016/0042-6822(80)90499-7. View

de la Luna S, Martinez C, Ortin J . Molecular cloning and sequencing of influenza virus A/Victoria/3/75 polymerase genes: sequence evolution and prediction of possible functional domains. Virus Res. 1989; 13(2):143-55. DOI: 10.1016/0168-1702(89)90012-9. View

10.

Tolpin M, Clements M, Levine M, Black R, Saah A, ANTHONY W . Evaluation of a phenotypic revertant of the A/Alaska/77-ts-1A2 reassortant virus in hamsters and in seronegative adult volunteers: further evidence that the temperature-sensitive phenotype is responsible for attenuation of ts-1A2 reassortant viruses. Infect Immun. 1982; 36(2):645-50. PMC: 351277. DOI: 10.1128/iai.36.2.645-650.1982. View

11.

Parkin N, Chiu P, Coelingh K . Temperature sensitive mutants of influenza A virus generated by reverse genetics and clustered charged to alanine mutagenesis. Virus Res. 1996; 46(1-2):31-44. DOI: 10.1016/s0168-1702(96)01373-1. View

12.

Ulmanen I, Broni B, KRUG R . Role of two of the influenza virus core P proteins in recognizing cap 1 structures (m7GpppNm) on RNAs and in initiating viral RNA transcription. Proc Natl Acad Sci U S A. 1981; 78(12):7355-9. PMC: 349265. DOI: 10.1073/pnas.78.12.7355. View

13.

Subbarao E, Park E, Lawson C, Chen A, Murphy B . Sequential addition of temperature-sensitive missense mutations into the PB2 gene of influenza A transfectant viruses can effect an increase in temperature sensitivity and attenuation and permits the rational design of a genetically engineered live.... J Virol. 1995; 69(10):5969-77. PMC: 189492. DOI: 10.1128/JVI.69.10.5969-5977.1995. View

14.

Braam J, Ulmanen I, KRUG R . Molecular model of a eucaryotic transcription complex: functions and movements of influenza P proteins during capped RNA-primed transcription. Cell. 1983; 34(2):609-18. DOI: 10.1016/0092-8674(83)90393-8. View

15.

Biswas S, Nayak D . Influenza virus polymerase basic protein 1 interacts with influenza virus polymerase basic protein 2 at multiple sites. J Virol. 1996; 70(10):6716-22. PMC: 190714. DOI: 10.1128/JVI.70.10.6716-6722.1996. View

16.

Glezen W, Payne A, Snyder D, Downs T . Mortality and influenza. J Infect Dis. 1982; 146(3):313-21. DOI: 10.1093/infdis/146.3.313. View

17.

Govaert T, Thijs C, Masurel N, Sprenger M, Dinant G, Knottnerus J . The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA. 1994; 272(21):1661-5. View

18.

Murphy B, Markoff L, Chanock R, Spring S, Maassab H, Kendal A . Genetic approaches to attenuation of influenza A viruses for man. Philos Trans R Soc Lond B Biol Sci. 1980; 288(1029):401-15. DOI: 10.1098/rstb.1980.0017. View

19.

McCauley J, Penn C . The critical cut-off temperature of avian influenza viruses. Virus Res. 1990; 17(3):191-8. DOI: 10.1016/0168-1702(90)90064-i. View

20.

Foster D, Talsma A, Ohmit S, Margulies J, Arden N, Monto A . Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol. 1992; 136(3):296-307. DOI: 10.1093/oxfordjournals.aje.a116495. View